QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass., February 05, 2025--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage ...

The drug in question, dubbed QLS‑111, has been created with Qlaris’ ATP-sensitive potassium channel modulator platform and is designed to lower intraocular pressure (IOP). The results ...

QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company ...

The biggest news is that the ALEXA 35 will now be available in several different Base Kits where you are essentially getting the same exact hardware, but with with different software to make it more ...